Ilhuicamina Daniel Limón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilhuicamina Daniel Limón has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Aleidy Patricio-Martínez
Laboratorio de Neurofarmacología, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla A.P. 72000, Puebla, Mexico
13 shared publications - Felipe Patricio
Facultad de Medicina Veterinaria y Zootecnia, Benemérita Universidad Autónoma de Puebla, Tecamachalco 75482, Puebla, Mexico
10 shared publications Liliana Mendieta
Laboratorio de Neuroquímica, Facultad de Ciencias Químicas - Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
5 shared publications- José Aguilera
Departament de Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, España
4 shared publications Claudia Sánchez-Maldonado
Laboratorio de Neurofarmacología, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma Puebla, Puebla, Puebla, Mexico
3 shared publicationsEleazar Ramírez
Laboratorio de Neurofarmacología, Facultad de Ciencias Químicas-Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
3 shared publications
Latest Publications
- 11 July 2026
- Published by Elsevier in Neuroscience
- Vol. 611, 450-460
Recombinant Hc-TeTx modulates TrkA-related signaling and preserves cholinergic integrity in the nucleus basalis magnocellularis after Aβ(25–35) injury
- 11 July 2026
- Published by Elsevier in Neuroscience
- Vol. 611, 450-460
Recombinant Hc-TeTx modulates TrkA-related signaling and preserves cholinergic integrity in the nucleus basalis magnocellularis after Aβ(25–35) injury
- Open Access
The Dopamine D3 Receptor as an Emerging Therapeutic Target in Parkinson’s Disease: Structural Advances, Signaling Bias and Neuroprotective Perspectives
The dopamine D3 receptor (D3R) has long been considered a secondary target in the treatment of Parkinson’s disease (PD), with therapeutic strategies primarily focused on D2 receptor–mediated motor control. However, accumulating evidence now supports D3R as a functionally distinct dopaminergic receptor subtype with specific relevance to non-motor symptom domains and dopaminergic signaling under hypodopaminergic conditions. Recent advances in high-resolution structural biology have elucidated the molecular basis of D3R/D2R discrimination, revealing how subtle residue-level and microstructural differences within a conserved G protein–coupled receptor framework shape ligand recognition and receptor activation. In parallel, the emergence of ligand-dependent biased signaling has refined current understanding of D3R pharmacology. Selected ligands can preferentially engage Gαi/o-mediated pathways while limiting β-arrestin recruitment and associated regulatory processes, providing a mechanistic rationale for more stable modulation of mesolimbic dopaminergic circuits involved in affective and motivational regulation. Beyond symptomatic modulation, preclinical studies suggest that D3R signaling may influence neuronal resilience, synaptic plasticity, and adaptive responses to dopaminergic injury; however, such effects remain experimental and have not been demonstrated in clinical PD. This review integrates recent structural, signaling, and functional insights into D3R biology, with particular emphasis on biased agonism and emerging therapeutic concepts. Although D3R-targeted strategies do not currently represent disease-modifying interventions, they offer a rational framework for the development of next-generation dopaminergic therapies aimed at improving precision, tolerability, and long-term signaling stability in Parkinson’s disease.
Open AccessThe Dopamine D3 Receptor as an Emerging Therapeutic Target in Parkinson’s Disease: Structural Advances, Signaling Bias and Neuroprotective Perspectives
The dopamine D3 receptor (D3R) has long been considered a secondary target in the treatment of Parkinson’s disease (PD), with therapeutic strategies primarily focused on D2 receptor–mediated motor control. However, accumulating evidence now supports D3R as a functionally distinct dopaminergic receptor subtype with specific relevance to non-motor symptom domains and dopaminergic signaling under hypodopaminergic conditions. Recent advances in high-resolution structural biology have elucidated the molecular basis of D3R/D2R discrimination, revealing how subtle residue-level and microstructural differences within a conserved G protein–coupled receptor framework shape ligand recognition and receptor activation. In parallel, the emergence of ligand-dependent biased signaling has refined current understanding of D3R pharmacology. Selected ligands can preferentially engage Gαi/o-mediated pathways while limiting β-arrestin recruitment and associated regulatory processes, providing a mechanistic rationale for more stable modulation of mesolimbic dopaminergic circuits involved in affective and motivational regulation. Beyond symptomatic modulation, preclinical studies suggest that D3R signaling may influence neuronal resilience, synaptic plasticity, and adaptive responses to dopaminergic injury; however, such effects remain experimental and have not been demonstrated in clinical PD. This review integrates recent structural, signaling, and functional insights into D3R biology, with particular emphasis on biased agonism and emerging therapeutic concepts. Although D3R-targeted strategies do not currently represent disease-modifying interventions, they offer a rational framework for the development of next-generation dopaminergic therapies aimed at improving precision, tolerability, and long-term signaling stability in Parkinson’s disease.
- Open Access
- 25 June 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1598011
The role of probiotics, prebiotics, and postbiotics: cellular and molecular pathways activated on glial cells in Alzheimer’s disease
Supplementation with prebiotics and probiotics can modulate the intestinal microbiota, returning it to a more physiological state; therefore, they can be considered as a possible treatment in many prevalent conditions, including neurodegenerative diseases. Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60 to 70% of cases. The neuropathological features of AD include neuritic plaques (extracellular deposits of the beta-amyloid protein, Aβ), neurofibrillary tangles (resulting from hyperphosphorylation of the tau protein), a predominantly cholinergic synaptic decrease, and the presence of inflammatory markers, all these characteristics together trigger the neurodegenerative process and cognitive deterioration. The etiology of AD is multifactorial, however, in recent years evidence has been shown on the significant association between dysbiosis, neuroinflammation, and neurodegeneration. In the present review, we will discuss the role of gut microbiota in the pathogenesis of AD, as well as the underlying mechanisms that trigger the use of probiotics, prebiotics, and postbiotics in neuroinflammation. Our attention will focus on the cellular and molecular mechanisms triggered by astrocytes and microglia, cells involved in mediating neuroinflammation and neurodegeneration in AD.
- 25 June 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1598011
Open AccessThe role of probiotics, prebiotics, and postbiotics: cellular and molecular pathways activated on glial cells in Alzheimer’s disease
Supplementation with prebiotics and probiotics can modulate the intestinal microbiota, returning it to a more physiological state; therefore, they can be considered as a possible treatment in many prevalent conditions, including neurodegenerative diseases. Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60 to 70% of cases. The neuropathological features of AD include neuritic plaques (extracellular deposits of the beta-amyloid protein, Aβ), neurofibrillary tangles (resulting from hyperphosphorylation of the tau protein), a predominantly cholinergic synaptic decrease, and the presence of inflammatory markers, all these characteristics together trigger the neurodegenerative process and cognitive deterioration. The etiology of AD is multifactorial, however, in recent years evidence has been shown on the significant association between dysbiosis, neuroinflammation, and neurodegeneration. In the present review, we will discuss the role of gut microbiota in the pathogenesis of AD, as well as the underlying mechanisms that trigger the use of probiotics, prebiotics, and postbiotics in neuroinflammation. Our attention will focus on the cellular and molecular mechanisms triggered by astrocytes and microglia, cells involved in mediating neuroinflammation and neurodegeneration in AD.
- Open Access
- 1 June 2023
- Published by FapUNIFESP (SciELO) in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
- Vol. 75 (3) , 376-380
Anthelmintic resistance against gastrointestinal nematodes in beef cattle: effect on liveweight gain of grazing livestock in Mexico
This study aimed to determine the efficacy and parasite resistance of levamisole (LV) and ivermectin (IVM) in beef cattle naturally infected with gastrointestinal nematodes, as well as the effect on the liveweight gain in a tropical wet region of Oaxaca, Mexico. From November 2019 to January 2020, sixty-six grazing calves were randomly allocated into three groups of twenty-two animals each, treated with LV or IVM or an untreated control group (day 0). Feces were collected 1 day before treatment and 15 days after treatment. The liveweight gain from each animal was recorded at days 0, 15, 30 and 45 post treatment. The LV group presented the highest reduction of eggs per gram (EPG) of feces, followed by the IVM group. Resistance to IVM was detected, although LV resistance was also suspected. The IVM group had significantly higher effective treatment at 93.5%, resulting in an increase (PP < 0.05) negative correlation was observed between EPG and weight gain for the LV (𝑟 = -0.46) and IVM groups (𝑟 = -0.32). LV and IVM showed a lack of efficacy against gastrointestinal nematodes, as well as an adequate capacity for EPG reduction but with IVM resistance and detrimental effects on growth performance in grazing beef cattle.
- 1 June 2023
- Published by FapUNIFESP (SciELO) in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
- Vol. 75 (3) , 376-380
Open AccessAnthelmintic resistance against gastrointestinal nematodes in beef cattle: effect on liveweight gain of grazing livestock in Mexico
This study aimed to determine the efficacy and parasite resistance of levamisole (LV) and ivermectin (IVM) in beef cattle naturally infected with gastrointestinal nematodes, as well as the effect on the liveweight gain in a tropical wet region of Oaxaca, Mexico. From November 2019 to January 2020, sixty-six grazing calves were randomly allocated into three groups of twenty-two animals each, treated with LV or IVM or an untreated control group (day 0). Feces were collected 1 day before treatment and 15 days after treatment. The liveweight gain from each animal was recorded at days 0, 15, 30 and 45 post treatment. The LV group presented the highest reduction of eggs per gram (EPG) of feces, followed by the IVM group. Resistance to IVM was detected, although LV resistance was also suspected. The IVM group had significantly higher effective treatment at 93.5%, resulting in an increase (PP < 0.05) negative correlation was observed between EPG and weight gain for the LV (𝑟 = -0.46) and IVM groups (𝑟 = -0.32). LV and IVM showed a lack of efficacy against gastrointestinal nematodes, as well as an adequate capacity for EPG reduction but with IVM resistance and detrimental effects on growth performance in grazing beef cattle.
- Open Access
- 3 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8164
β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease
The β-secretase-1 enzyme (BACE-1) performs a key role in the production of beta-Amyloid protein (Aβ), which is associated with the development of Alzheimer’s disease (AD). The inhibition of BACE-1 has been an important pharmacological strategy in the treatment of this neurodegenerative disease. This study aims to identify new potential candidates for the treatment of Alzheimer’s with the help of in silico studies, such as molecular docking and ADME prediction, from a broad list of candidates provided by the DrugBank database. From this analysis, 1145 drugs capable of interacting with the enzyme with a higher coupling energy than Verubecestat were obtained, subsequently only 83 presented higher coupling energy than EJ7. Applying the oral route of administration as inclusion criteria, only 41 candidates met this requirement; however, 6 of them are associated with diagnostic tests and not treatment, so 33 candidates were obtained. Finally, five candidates were identified as possible BACE-1 inhibitors drugs: Fluphenazine, Naratriptan, Bazedoxifene, Frovatriptan, and Raloxifene. These candidates exhibit pharmacophore-specific features, including the indole or thioindole group, and interactions with key amino acids in BACE-1. Overall, this study provides insights into the potential use of in silico methods for drug repurposing and identification of new candidates for the treatment of Alzheimer’s disease, especially those targeting BACE-1.
- 3 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8164
Open Accessβ-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease
The β-secretase-1 enzyme (BACE-1) performs a key role in the production of beta-Amyloid protein (Aβ), which is associated with the development of Alzheimer’s disease (AD). The inhibition of BACE-1 has been an important pharmacological strategy in the treatment of this neurodegenerative disease. This study aims to identify new potential candidates for the treatment of Alzheimer’s with the help of in silico studies, such as molecular docking and ADME prediction, from a broad list of candidates provided by the DrugBank database. From this analysis, 1145 drugs capable of interacting with the enzyme with a higher coupling energy than Verubecestat were obtained, subsequently only 83 presented higher coupling energy than EJ7. Applying the oral route of administration as inclusion criteria, only 41 candidates met this requirement; however, 6 of them are associated with diagnostic tests and not treatment, so 33 candidates were obtained. Finally, five candidates were identified as possible BACE-1 inhibitors drugs: Fluphenazine, Naratriptan, Bazedoxifene, Frovatriptan, and Raloxifene. These candidates exhibit pharmacophore-specific features, including the indole or thioindole group, and interactions with key amino acids in BACE-1. Overall, this study provides insights into the potential use of in silico methods for drug repurposing and identification of new candidates for the treatment of Alzheimer’s disease, especially those targeting BACE-1.
- 23 December 2022
- Published by Elsevier in Neuroscience Letters
- Vol. 795, 137030
Amyloid-β (25–35) induces the morphological alteration of dendritic spines and decreases NR2B and PSD-95 expression in the hippocampus
- 23 December 2022
- Published by Elsevier in Neuroscience Letters
- Vol. 795, 137030
Amyloid-β (25–35) induces the morphological alteration of dendritic spines and decreases NR2B and PSD-95 expression in the hippocampus
- Open Access
- 2 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 945836
Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats
Cannabidiol (CBD) presents antiparkinsonian properties and neuromodulatory effects, possibly due to the pleiotropic activity caused at multiple molecular targets. Recently, the GPR55 receptor has emerged as a molecular target of CBD. Interestingly, GPR55 mRNA is expressed in the external globus pallidus (GPe) and striatum, hence, it has been suggested that its activity is linked to motor dysfunction in Parkinson’s disease (PD). The present study aimed to evaluate the effect of the intrapallidal injection of both CBD and a selective GPR55 antagonist (CID16020046) on motor asymmetry, fine motor skills, and GAD-67 expression in hemiparkinsonian rats. The hemiparkinsonian animal model applied involved the induction of a lesion in male Wistar rats via the infusion of the neurotoxin 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle via stereotaxic surgery. After a period of twenty days, a second surgical procedure was performed to implant a guide cannula into the GPe. Seven days later, lysophosphatidylinositol (LPI), CBD, or CID16020046 were injected once a day for three consecutive days (from the 28th to the 30th day post-lesion). Amphetamine-induced turning behavior was evaluated on the 14th and 30th days post-injury. The staircase test and fine motor skills were evaluated as follows: the rats were subject to a ten-day training period prior to the 6-OHDA injury; from the 15th to the 19th days post-lesion, the motor skills alterations were evaluated under basal conditions; and, from the 28th to the 30th day post-lesion, the pharmacological effects of the drugs administered were evaluated. The results obtained show that the administration of LPI or CBD generated lower levels of motor asymmetry in the turning behavior of hemiparkinsonian rats. It was also found that the injection of CBD or CID16020046, but not LPI, in the hemiparkinsonian rats generated significantly superior performance in the staircase test, in terms of the use of the forelimb contralateral to the 6-OHDA-induced lesion, when evaluated from the 28th to the 30th day post-lesion. Similar results were also observed for superior fine motor skills performance for pronation, grasp, and supination. Finally, the immunoreactivity levels were found to decrease for the GAD-67 enzyme in the striatum and the ipsilateral GPe of the rats injected with CBD and CID16020046, in contrast with those lesioned with 6-OHDA. The results obtained suggest that the inhibitory effects of CBD and CID16020046 on GPR55 in the GPe could be related to GABAergic overactivation in hemiparkinsonism, thus opening new perspectives to explain, at a cellular level, the reversal of the motor impairment observed in PD models.
- 2 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 945836
Open AccessIntrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats
Cannabidiol (CBD) presents antiparkinsonian properties and neuromodulatory effects, possibly due to the pleiotropic activity caused at multiple molecular targets. Recently, the GPR55 receptor has emerged as a molecular target of CBD. Interestingly, GPR55 mRNA is expressed in the external globus pallidus (GPe) and striatum, hence, it has been suggested that its activity is linked to motor dysfunction in Parkinson’s disease (PD). The present study aimed to evaluate the effect of the intrapallidal injection of both CBD and a selective GPR55 antagonist (CID16020046) on motor asymmetry, fine motor skills, and GAD-67 expression in hemiparkinsonian rats. The hemiparkinsonian animal model applied involved the induction of a lesion in male Wistar rats via the infusion of the neurotoxin 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle via stereotaxic surgery. After a period of twenty days, a second surgical procedure was performed to implant a guide cannula into the GPe. Seven days later, lysophosphatidylinositol (LPI), CBD, or CID16020046 were injected once a day for three consecutive days (from the 28th to the 30th day post-lesion). Amphetamine-induced turning behavior was evaluated on the 14th and 30th days post-injury. The staircase test and fine motor skills were evaluated as follows: the rats were subject to a ten-day training period prior to the 6-OHDA injury; from the 15th to the 19th days post-lesion, the motor skills alterations were evaluated under basal conditions; and, from the 28th to the 30th day post-lesion, the pharmacological effects of the drugs administered were evaluated. The results obtained show that the administration of LPI or CBD generated lower levels of motor asymmetry in the turning behavior of hemiparkinsonian rats. It was also found that the injection of CBD or CID16020046, but not LPI, in the hemiparkinsonian rats generated significantly superior performance in the staircase test, in terms of the use of the forelimb contralateral to the 6-OHDA-induced lesion, when evaluated from the 28th to the 30th day post-lesion. Similar results were also observed for superior fine motor skills performance for pronation, grasp, and supination. Finally, the immunoreactivity levels were found to decrease for the GAD-67 enzyme in the striatum and the ipsilateral GPe of the rats injected with CBD and CID16020046, in contrast with those lesioned with 6-OHDA. The results obtained suggest that the inhibitory effects of CBD and CID16020046 on GPR55 in the GPe could be related to GABAergic overactivation in hemiparkinsonism, thus opening new perspectives to explain, at a cellular level, the reversal of the motor impairment observed in PD models.
- Open Access
- 20 May 2022
- Published by Wiley in Behavioural Neurology
- Vol. 2022, 1-20
Prophylactic Zinc Administration Combined with Swimming Exercise Prevents Cognitive-Emotional Disturbances and Tissue Injury following a Transient Hypoxic-Ischemic Insult in the Rat
Exercise performance and zinc administration individually yield a protective effect on various neurodegenerative models, including ischemic brain injury. Therefore, this work was aimed at evaluating the combined effect of subacute prophylactic zinc administration and swimming exercise in a transient cerebral ischemia model. The prophylactic zinc administration (2.5 mg/kg of body weight) was provided every 24 h for four days before a 30 min common carotid artery occlusion (CCAO), and 24 h after reperfusion, the rats were subjected to swimming exercise in the Morris Water Maze (MWM). Learning was evaluated daily for five days, and memory on day 12 postreperfusion; anxiety or depression-like behavior was measured by the elevated plus maze and the motor activity by open-field test. Nitrites, lipid peroxidation, and the activity of superoxide dismutase (SOD) and catalase (CAT) were assessed in the temporoparietal cortex and hippocampus. The three nitric oxide (NO) synthase isoforms, chemokines, and their receptor levels were measured by ELISA. Nissl staining evaluated hippocampus cytoarchitecture and Iba-1 immunohistochemistry activated the microglia. Swimming exercise alone could not prevent ischemic damage but, combined with prophylactic zinc administration, reversed the cognitive deficit, decreased NOS and chemokine levels, prevented tissue damage, and increased Iba-1 (+) cell number. These results suggest that the subacute prophylactic zinc administration combined with swimming exercise, but not the individual treatment, prevents the ischemic damage on day 12 postreperfusion in the transient ischemia model.
- 20 May 2022
- Published by Wiley in Behavioural Neurology
- Vol. 2022, 1-20
Open AccessProphylactic Zinc Administration Combined with Swimming Exercise Prevents Cognitive-Emotional Disturbances and Tissue Injury following a Transient Hypoxic-Ischemic Insult in the Rat
Exercise performance and zinc administration individually yield a protective effect on various neurodegenerative models, including ischemic brain injury. Therefore, this work was aimed at evaluating the combined effect of subacute prophylactic zinc administration and swimming exercise in a transient cerebral ischemia model. The prophylactic zinc administration (2.5 mg/kg of body weight) was provided every 24 h for four days before a 30 min common carotid artery occlusion (CCAO), and 24 h after reperfusion, the rats were subjected to swimming exercise in the Morris Water Maze (MWM). Learning was evaluated daily for five days, and memory on day 12 postreperfusion; anxiety or depression-like behavior was measured by the elevated plus maze and the motor activity by open-field test. Nitrites, lipid peroxidation, and the activity of superoxide dismutase (SOD) and catalase (CAT) were assessed in the temporoparietal cortex and hippocampus. The three nitric oxide (NO) synthase isoforms, chemokines, and their receptor levels were measured by ELISA. Nissl staining evaluated hippocampus cytoarchitecture and Iba-1 immunohistochemistry activated the microglia. Swimming exercise alone could not prevent ischemic damage but, combined with prophylactic zinc administration, reversed the cognitive deficit, decreased NOS and chemokine levels, prevented tissue damage, and increased Iba-1 (+) cell number. These results suggest that the subacute prophylactic zinc administration combined with swimming exercise, but not the individual treatment, prevents the ischemic damage on day 12 postreperfusion in the transient ischemia model.
- Open Access
- 3 May 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 867825
Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
Evidence suggests that SARS-CoV-2 entry into the central nervous system can result in neurological and/or neurodegenerative diseases. In this review, routes of SARS-Cov-2 entry into the brain via neuroinvasive pathways such as transcribrial, ocular surface or hematogenous system are discussed. It is argued that SARS-Cov-2-induced cytokine storm, neuroinflammation and oxidative stress increase the risk of developing neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Further studies on the effects of SARS-CoV-2 and its variants on protein aggregation, glia or microglia activation, and blood-brain barrier are warranted.
- 3 May 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 867825
Open AccessNeuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
Evidence suggests that SARS-CoV-2 entry into the central nervous system can result in neurological and/or neurodegenerative diseases. In this review, routes of SARS-Cov-2 entry into the brain via neuroinvasive pathways such as transcribrial, ocular surface or hematogenous system are discussed. It is argued that SARS-Cov-2-induced cytokine storm, neuroinflammation and oxidative stress increase the risk of developing neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Further studies on the effects of SARS-CoV-2 and its variants on protein aggregation, glia or microglia activation, and blood-brain barrier are warranted.
- 6 April 2022
- Published by Springer Nature in Multimedia Tools and Applications
- Vol. 81 (21) , 30329-30350
A deep learning-based approach for real-time rodent detection and behaviour classification
- 6 April 2022
- Published by Springer Nature in Multimedia Tools and Applications
- Vol. 81 (21) , 30329-30350
A deep learning-based approach for real-time rodent detection and behaviour classification